TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00805909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-0401
Description: 5 daily infusions with escalating doses of NI-0401
Study: NCT02323490

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: with microfractures
Description: following meniscal repair, microfractures will be created on the intercondylar and outer part of femoral condyle (outside of joint surface), lateral or medial, respectively

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: without microfractures
Description: standard procedure meniscal repair without augmentation.
Study: NCT02494713

Intervention type: DRUG
Group type: OTHER
Intervention: Degarelix
Description: Subcutaneous injection, once/month for 4 months

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: 20 mg/m2 as a 24-hour intravenous infusion on day 1 each week, weeks 1, 3, and 5

Intervention type: DRUG
Group type: OTHER
Intervention: Ketoconazole
Description: 400 mg orally 3 times daily for 7 days, in weeks 1, 3, and 5

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: 35 mg/m2 intravenously on day 1 of each week, weeks 2, 4, and 6

Intervention type: DRUG
Group type: OTHER
Intervention: Estramustine
Description: 280 mg orally 3 times daily for 7 days, in weeks 2, 4, and 6
Study: NCT05131906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait task and activity of daily living task
Description: use of lasers on shoes to potentially minimize freezing of gait
Study: NCT03629158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLIMB intervention
Description: The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks. Sessions range from 1-2 hours in length, including questionnaire completion. Participants will be given information and taught relevant skills to increase engagement in lifestyle behaviors relevant to cardiac health.
Study: NCT02161874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T3 with DCD tapered Prevail implant
Description: T3 with DCD implant with Certain (internal) connection and platform-switch design

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nanotite Certain tapered implant
Description: Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design
Study: NCT03784261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Salirumab
Description: To examine the effects of salirumab in RA patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Salirumab
Description: To examine the effects of salirumab in RA patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Salirumab
Description: To examine the effects of salirumab in RA patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Tocilizmab
Description: To examine the effects of tocilizmab in RA patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Tocilizmab
Description: To examine the effects of tocilizmab in RA patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Tocilizmab
Description: To examine the effects of tocilizmab in RA patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Abatacept
Description: To examine the effects of abatacept in RA patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Abatacept
Description: To examine the effects of abatacept in RA patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Abatacept
Description: To examine the effects of abatacept in RA patients
Study: NCT04172298

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham electroacupuncture (EA) session
Description: The stainless steels acupuncture needles inserted into the subcutaneous layer of Zusanli (cathode) and Shangjuxu acupints (anion) , and the needles connected to EA stimulator, but no electric discharge for 30 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zusanli session
Description: The acupuncture needles inserted into Zusanli (cathode) and Shangjuxu acupoints (anion), and twisting obtain qi, and the needles then connected to EA stimulator, the frequency was 2 Hz, the duration was 30 min, and the intensity was visual slightly muscle contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shaohai session
Description: The methods were identical Zusanli group, but Shaohai acupoint (cathode), and 3 cm below Shaohai (anion).
Study: NCT01839942

Intervention type: PROCEDURE
Intervention: hernia gap closure
Description: type of gap closure during laparoscopic repair of a ventral hernia: none, extracorporal, intracorporal

Intervention type: PROCEDURE
Intervention: hernia gap closure
Description: type of gap closure during laparoscopic repair of a ventral hernia: none, extracorporal, intracorporal

Intervention type: PROCEDURE
Intervention: extracorporal suturing of gap
Description: ventral hernia gap is sutured extracorporally
Study: NCT00167206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplant
Description: Bone marrow failure may be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thymic Shielding During Radiation
Description: protecting the thymus during total body radiation (450 cGy administered)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Six days before the stem cells are given (day -6), subjects will receive total body irradiation with thymic shielding. Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Fludarabine
Description: Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line
Study: NCT00545649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Study: NCT02213731

Intervention type: OTHER
Group type: OTHER
Intervention: Holter monitoring
Description: Subjects will wear holter monitors at baseline, 6 months and 12 months.
Study: NCT03497403

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket preservation control
Description: After a tooth was extracted, the adjacent gum tissue was fully reflected, bone graft (FDBA) and non-cross-linked barrier membrane (Bio-Gide) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation experimental
Description: After a tooth was extracted, the adjacent gum tissue was minimally reflected, bone graft (FDBA) and cross-linked barrier membrane (OssixPlus) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
Study: NCT02250053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT03965338

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: fMRI
Description: Screening
Study: NCT03656224

Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT01943942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Description: Test product
Study: NCT02274155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-OX40 antibody administration
Description: Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-OX40 antibody administration
Description: Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-OX40 antibody administration
Description: Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical Resection of Tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical Resection of Tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical Resection of Tumor
Study: NCT02251249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol concentration time curve from 0 to 120 min
Description: It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets Brilique ® 90 mg) with water. Then Paracetamol concentration is followed by the realization of the curve of concentration of paracetamol in plasma samples. These samples are taken at 15 min intervals during the first 2 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol concentration time curve from 0 to 120 min
Description: It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets Brilique ® 90 mg) with water. Then Paracetamol concentration is followed by the realization of the curve of concentration of paracetamol in plasma samples. These samples are taken at 15 min intervals during the first 2 hours.
Study: NCT01885169

Intervention type: BIOLOGICAL
Intervention: Flumist®
Description: The three cohorts will receive Flumist® and will be swabbed for inflammatory markers and viral shedding.

Intervention type: BIOLOGICAL
Intervention: Flumist®
Description: The three cohorts will receive Flumist® and will be swabbed for inflammatory markers and viral shedding.

Intervention type: BIOLOGICAL
Intervention: Flumist®
Description: The three cohorts will receive Flumist® and will be swabbed for inflammatory markers and viral shedding.
Study: NCT01460225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lubiprostone
Description: 24 micrograms twice daily for 1 week
Study: NCT03016351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
Study: NCT04121897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapist Education and Massage for Parents of Extremely Preterm Infants
Description: TEMPO includes these components:~* Early Parent Education Session~* Weekly Parent Education Sessions~* Infant Massage Parent Education Sessions~* Discharge Parent Education Session~* Parent Education Post-Discharge~* Bi-weekly emails (or texts)~* 2 Month Follow-up Massage Review Session
Study: NCT03394677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-501 0.5% ointment
Description: Patients will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Description: Placebo comparator - ointment twice daily (BID) for 4 weeks.
Study: NCT01306214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 low dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 high dose once daily
Study: NCT00779753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Solution with different amount of Lysine
Description: The infants will be placed on a standard Primene solution for the first 24 hours of the study to obtain baseline values. During the second 24 hours they will receive an amino acid solution that has a different amount of lysine currently found in Primene, all lipid, CHO, minerals, vitamins and trace elements will remain unchanged. The Parenteral lysine will be studied at the following intake levels: 100, 110, 120, 130, 135, 140, 145, 150 , 155, 165, 170, 180, 200, 230, 245, 260mg/kg/d. The minimum energy intake will be 85-90 kcal/kg/day.
Study: NCT04116775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant
Description: A total of 100 mL of a mixture of stool and saline will be transplanted via endoscopy once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg administered as a 30 minute infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Daily oral dose.
Study: NCT02954588

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pyridoxamine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pyridoxamine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02874716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuberculosis Program (PPIA)
Description: The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free sputum microscopy, free digital chest X-ray, free or subsidized drug-susceptibility testing (DST), free first line anti-TB treatment), (2) training or certified medical education sessions for the providers from the PPIA, and (3) financial incentives to engaged providers for patient registration, diagnostic testing, treatment initiation, and treatment adherence. Meanwhile, health camps, advertising, and other advocacy efforts are aimed to raise awareness in the communities.
Study: NCT01359020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen, dipyrone, acetaminophen
Description: The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen, dipyrone, acetaminophen
Description: The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
Study: NCT02671500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: SOF/VEL (400/100 mg) FDC tablet administered orally once daily
Study: NCT01359020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen, dipyrone, acetaminophen
Description: The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
Study: NCT03958006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Description: Tumor resection with cochlear implant
Study: NCT04382846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide
Study: NCT01390155

Intervention type: PROCEDURE
Intervention: Measurement of coronary collateral flow index
Description: One-minute balloon occlusion of the proximal left anterior descending coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.

Intervention type: PROCEDURE
Intervention: Measurement of coronary collateral flow index
Description: One-minute balloon occlusion of the proximal left circumflex artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.

Intervention type: PROCEDURE
Intervention: Measurement of coronary collateral flow index
Description: One-minute balloon occlusion of the proximal right coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.

Intervention type: PROCEDURE
Intervention: Measurement of coronary collateral flow index
Description: One-minute balloon occlusion of the target vessel (the vessel which shows a significant stenosis and accordingly requires a therapeutical intervention by balloon angioplasty and stenting) inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
Study: NCT03725111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: venous compression
Description: venous compression
Study: NCT04385758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes-REM Program
Description: A comprehensive community paramedicine management program designed to support adults with uncontrolled diabetes and a recent emergency department visit or hospitalization
Study: NCT00297804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Express Paclitaxel-Eluting Coronary Stent System
Description: Paclitaxel-Eluting Coronary Stent System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control stent
Description: control stent
Study: NCT00873262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Skin test panel and desensitization kit
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the appropriate hormone at the same concentration as it was used in the skin test as follows:~1. Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~2. Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~3. Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Skin test panel and solvent
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the solvent as follows:~1. Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~2. Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~3. Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml
Study: NCT00269906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01895790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pancreatic Duct Stent Placement
Study: NCT02222298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video assisted ablation of pilonidal sinus
Description: A 5-phases' technique. The 1st phase is to insert the endoscope through the external opening (orifice). In the patients that had more than one opening the lower pit is used for access. The 2nd phase is to identify the sinus cavity and its lateral tracks. The endoscope is advanced along the pathway using slow movements, left/right and up/down. These manoeuvres and the saline solution, used as distension medium, allow the sinus cavity to accommodate the endoscope. Additionally mechanical adhesiolysis with the forceps grasping could be useful. The 3rd phase is to identify the presence of hair and its removal. The 4th phase phase is to obtain complete ablation of sinus cavity. The sinus cavity and its lateral tracks are destroyed with the electrode under continuous direct vision. The 5th phase is to obtain the accurate cleaning of sinus cavity. The saline solution flow allows the elimination of any necrotic material. A Volkmann spoon could be useful to complete the cleaning.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bascom Cleft lift procedure
Study: NCT03591133

Intervention type: DRUG
Group type: OTHER
Intervention: TS-143

Intervention type: DRUG
Group type: OTHER
Intervention: TS-143

Intervention type: DRUG
Group type: OTHER
Intervention: TS-143

Intervention type: DRUG
Group type: OTHER
Intervention: TS-143

Intervention type: DRUG
Group type: OTHER
Intervention: TS-143

Intervention type: DRUG
Group type: OTHER
Intervention: TS-143

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT04678531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Swabs containing tea tree oil and chamomile oil
Description: Swabs will be used in 26 patients for 8 weeks and will be discontinued in the following 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baby shampoo
Description: Baby shampoo will be used in 23 patients for 8 weeks and will be discontinued in the following 4 weeks.
Study: NCT02149238

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flavanol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: methylxanthine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flavanol + methylxanthine